Oct 26 (Reuters) - Indian drugmaker Mankind Pharma reported an over 39% jump in second-quarter profit on Monday, helped by ...
NDTV Profit on MSN
Mankind Pharma Q2 review: Jefferies, Kotak retain buy after strong earnings. Check target prices
Jefferies maintained its Buy' rating on Mankind Pharma but lowered its target price to Rs 2,900 from Rs 3,220, citing a stronger growth outlook and easing integration challenges.
For the first half of FY27, revenue from operations rose 15.1% YoY to ₹8,368 crore. EBITDA increased 26% to ₹2,235 crore, ...
Mankind Pharma’s operating margin widened to 27% from 24.9% a year earlier. Its board also approved plans to merge two wholly ...
A New Delhi drugmaker, India's fourth largest by its own count, that sells branded medicines and consumer health brands at ...
The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and ...
The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands ...
Mankind Pharma to acquire 70% stake in Belgium-based Armed Cell Therapeutics B.V. for EUR 48 million, marking its entry into ...
Mankind Pharma reported a 39.2% increase in net profit to ₹712 crore for Q2, with revenue from operations rising 17.3% to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results